See more : Photomyne Ltd (PHTM.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Arcturus Therapeutics Holdings Inc. (ARCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcturus Therapeutics Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Inhibrx, Inc. Ex-distribution When-Issued (INBXV) Income Statement Analysis – Financial Results
- Angkor Resources Corp. (ANK.V) Income Statement Analysis – Financial Results
- Greenland Holdings Corporation Limited (600606.SS) Income Statement Analysis – Financial Results
- Recharge Resources Ltd. (RR.CN) Income Statement Analysis – Financial Results
- Dian Diagnostics Group Co.,Ltd. (300244.SZ) Income Statement Analysis – Financial Results
Arcturus Therapeutics Holdings Inc. (ARCT)
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.75M | 205.76M | 12.36M | 9.54M | 20.79M | 15.75M | 13.00M | 20.38M | 6.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.96M | 143.05M | 171.86M | 55.95M | 32.44M | 16.98M | 410.00K | 294.00K | 51.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 154.79M | 62.70M | -159.50M | -46.41M | -11.65M | -1.23M | 12.59M | 20.09M | 6.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.13% | 30.48% | -1,290.57% | -486.50% | -56.04% | -7.80% | 96.85% | 98.56% | 99.17% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 192.13M | 147.75M | 173.76M | 57.85M | 33.64M | 16.98M | 15.92M | 18.39M | 13.46M | 25.11M | 7.07M | 818.00K | 1.82M |
| General & Administrative | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Other Expenses | 0.00 | -244.00K | 0.00 | 0.00 | 0.00 | 0.00 | -348.00K | 1.42M | 1.25M | 2.13M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 235.95M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Cost & Expenses | 245.00M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Interest Income | 17.36M | 2.58M | 753.00K | 470.00K | 408.00K | 514.00K | 89.00K | 798.00K | 338.00K | 239.00K | 22.00K | 2.00K | 21.00K |
| Interest Expense | 767.00K | 420.00K | 2.67M | 361.00K | 446.00K | 186.00K | 150.00K | 295.00K | 251.00K | 2.00K | 197.00K | 80.00K | 44.00K |
| Depreciation & Amortization | 2.96M | 1.53M | 1.19M | 882.00K | 684.00K | 582.00K | 410.00K | 294.00K | 51.00K | 31.00K | 8.00K | 7.00K | 6.00K |
| EBITDA | -24.17M | 13.70M | -201.66M | -70.64M | -24.42M | -20.72M | -10.34M | -947.00K | -1.72M | -32.81M | -10.28M | -1.51M | -3.92M |
| EBITDA Ratio | -15.32% | 5.67% | -1,621.42% | -752.56% | -122.88% | -133.42% | -79.56% | -123.18% | -320.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.21M | 12.18M | -202.85M | -71.52M | -25.51M | -21.81M | -10.49M | -25.17M | -19.70M | -33.08M | -10.29M | -1.50M | -3.91M |
| Operating Income Ratio | -49.58% | 5.92% | -1,641.33% | -749.81% | -122.72% | -138.46% | -80.72% | -123.48% | -320.92% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 50.32M | -1.53M | -822.00K | -624.00K | -478.00K | 26.00K | -409.00K | -536.00K | 11.00K | 227.00K | -197.00K | -78.00K | -23.00K |
| Income Before Tax | -27.89M | 10.64M | -203.67M | -72.15M | -25.99M | -21.79M | -10.90M | -24.53M | -19.40M | -32.85M | -10.49M | -1.58M | -3.93M |
| Income Before Tax Ratio | -17.68% | 5.17% | -1,647.98% | -756.35% | -125.02% | -138.29% | -83.87% | -120.35% | -316.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.84M | 1.30M | 3.19M | -784.00K | -270.00K | 212.00K | 1.00K | 73.00K | 51.00K | -17.00K | 61.00K | 65.00K | 21.00K |
| Net Income | -29.73M | 9.35M | -206.86M | -71.36M | -25.72M | -21.79M | -10.90M | -24.60M | -19.45M | -32.83M | -10.55M | -1.58M | -3.93M |
| Net Income Ratio | -18.84% | 4.54% | -1,673.78% | -748.13% | -123.72% | -138.29% | -83.87% | -120.71% | -316.86% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| EPS Diluted | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| Weighted Avg Shares Out | 26.63M | 26.45M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
| Weighted Avg Shares Out (Dil) | 26.63M | 27.09M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Arcturus: Interim Readout Of Rare Disease Data In Coming Months
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
New Strong Sell Stocks for August 10th
Why Shares of Arcturus Therapeutics Dropped on Tuesday
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports